Free Trial

Protagenic Therapeutics Q3 2023 Earnings Report

Protagenic Therapeutics logo
$0.39 -0.03 (-7.27%)
As of 04:00 PM Eastern

Protagenic Therapeutics EPS Results

Actual EPS
-$0.32
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Protagenic Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protagenic Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Protagenic Therapeutics Earnings Headlines

Protagenic Therapeutics adjusts stock option prices
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Protagenic Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protagenic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagenic Therapeutics and other key companies, straight to your email.

About Protagenic Therapeutics

Protagenic Therapeutics (NASDAQ:PTIX), a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Protagenic Therapeutics Profile

More Earnings Resources from MarketBeat